ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0759

Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry

Piero Ruscitti1, Antonio Vitale2, Ilenia Di Cola1, Roberto giacomelli3 and Luca Cantarini4, 1University of L'Aquila, L'Aquila, Italy, 2University of Siena, Siena, Italy, 3University of Rome Campus Biomedico, Rome, Italy, 4Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy

Meeting: ACR Convergence 2023

Keywords: Autoinflammatory diseases, macrophage activation syndrome, Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Still’s disease is a rare inflammatory disorder, these patients have a highly heterogeneous disease according to age of onset, clinical presentation, presence of life-threatening complications, and outcomes. Thus, we aimed at deriving and validating disease clusters in a multicentre, observational, prospective study to stratify these patients.

Methods: Patients included in GIRRCS AOSD-study group and AIDA Network Still Disease Registry were selected to be assessed in this analysis if clinical variables selected for cluster analysis were available [i.e., age, systemic score, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and ferritin]. A cluster analysis was performed to devise deeper levels of categorization. The k-means algorithm with Euclidean metric was performed, setting 100 random assignments to the cluster seeds. Z-scores were also provided to account for the different units of the selected variables. The Elbow plot was used to devise an adequate number of clusters, avoiding too large choice which could underwent to overfitting. Besides the cluster plot enabled the view of the separation among clusters using the first two principal components. After that a descriptive assessment of the clusters was performed.

Results: By combining clinical selected variables, the K-means clustering assessment provided 4 clusters based on means standardized according to z-scores on 349 patients. The “within” and “between” separation properties were also derived. Within cluster sum of squares (SS) by cluster was estimated: i. cluster 1: 251.69; ii. cluster 2: 283.22; iii. cluster 3: 159.98; iv. cluster 4: 323.76. SSbetween/SStotal was derived to be 41.5%. The latter is not particularly high, but not affected by overfitting phenomena. In fact, the derived clusters showed reasonable “within” and “between” variability properties. After that, randomly sampling 50% of the original records, the same number of clusters was provided by the elbow plot with a similar SSbetween/SStotal of 42.6%.

All clusters mainly presented fever, skin rash, and joint involvement but each one of these has some different clinical features from others. Cluster 1 (“Juvenile/Transitional”) was composed by 115 patients distinguished by the lowest value of age and characterized by skin rash myalgia, sore throat, and splenomegaly. Cluster 2 (“Common”) included 128 patients identified by the lowest levels of ESR, ferritin, and systemic score; multiorgan manifestations were less frequently observed. Cluster 3 (“Hyperferritinemic”) comprised 31 patients categorised by the highest levels of CRP and ferritin, they were characterized by fever and joint involvement. Cluster 4 (“Catastrophic”) contained 75 patients derived by the highest values of age and systemic score. Myalgia, sore throat, liver involvement, and life-threatening complications, leading to a high mortality rate, were observed in these patients.

Conclusion: Four patient clusters in Still’s disease may be recognized by a multidimensional characterization. Each one of these has some different clinical features from others; cluster 4 was burdened by an increased rate of life-threatening complications and mortality, suggesting a more severe patient group.


Disclosures: P. Ruscitti: None; A. Vitale: None; I. Di Cola: None; R. giacomelli: None; L. Cantarini: None.

To cite this abstract in AMA style:

Ruscitti P, Vitale A, Di Cola I, giacomelli R, Cantarini L. Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/derivation-and-validation-of-four-patient-clusters-in-stills-disease-results-from-girrcs-aosd-study-group-and-aida-network-still-disease-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/derivation-and-validation-of-four-patient-clusters-in-stills-disease-results-from-girrcs-aosd-study-group-and-aida-network-still-disease-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology